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Objective. To evaluate the incidence of deep vein thrombosis in hospitalized Chinese medical patients and the impact of
DVT prophylaxis. Methods. All cases of conﬁrmed proximal DVT from 1 January 2005 to 31 December 2008 were reviewed
retrospectively to determine the presence of risk factors and whether DVT developed: during hospitalization in medical wards
or in case of readmission with a diagnosis of DVT within 14 days of discharge from a recent admission to medical wards. The
impact ofprophylaxis will be estimated by comparingthe annual incidence of proximal DVT amongmedical patients hospitalized
from 2005 to 2007 with that of 2008 (DVT prophylaxis commonly used). Results. From 1 January 2005 to 31 December 2008,
3938Doppler ultrasoundstudies were performed forsuspected DVT. ProximalDVT wasdiagnosedin 687patients.The calculated
incidence of proximal DVT among medical patients hospitalized for at least two days was 1.8%, 2%, and 1.7% for the year 2005,
2006, and 2007, respectively. The incidence was 1.1% for 2008 (P<. 001). Conclusion. Proximal DVT was substantial in Chinese
medical patients, and DVT prophylaxis might reduce such risk.
1.Introduction
Deep venous thrombosis (DVT) and pulmonary embolism
(PE) are common and serious complications occurring in
hospitalized patients [1, 2]. Many medical conditions such
as malignancy, neurological diseases with paresis, cardiac
failure, and acute myocardial infarction are associated with
increased risk of thromboembolism [3]. Hospitalization for
an acute medical illness is independently associated with
about an eightfold increased relative risk for VTE [4]a n d
accounts for almost one quarter of all VTE events within the
general population [5]. Recently completed trials comparing
low-molecular-weight heparins (LMWH) or pentasacharide
with placebo controls have provided convincing evidence
for VTE prevention in this patient population [6–8]. There
was little data about the incidence of DVT among Chinese
patients admitted to a medical ward. In the past, it was
widely believed that the incidence of DVT was much
lower among the Chinese population than Caucasians, and
prophylaxis was generally considered not necessary. Recent
studies had shown that the incidence of postoperative
DVT in Asian countries was signiﬁcant [9, 10]A s i a n
patients with hip fractures, undergoing total hip and total
knee replacementswithoutpharmacological prophylaxishad
postoperative DVT rates of 17–58% and proximal DVT
rates of 5.8–17.1%. These rates were comparable to that
reported in Western populations.. In a retrospective analysis
[11], we estimated that the incidence of proximal DVT
among Chinese patients admitted to general medical wards
was at least three per one thousand patients. Among the
medical patients who developed proximal DVT during their
hospital stay or within a week of discharge from a medical
ward, most of them had risk factors such as malignancy
(40%), infections (21%), congestive heart failure (13%),
and stroke (7%). In a prospective study [12]u s i n gd -
dimer screening, the incidence of DVT for Chinese medical
patients staying for two or more days was at least 10 per
1000. Among patients with risk factor such as malignancy,
stroke heart failure or respiratory failure, the incidence
of proximal DVT ranged between 3.8 and 6.3% and was2 Thrombosis
Table 1
Year 2005 2006 2007 2008 2008 versus 2005–7
Proximal DVT incidence (cases detected) 1.8% (182) 2.0% (204) 1.7% (173) 1.1% (128) P<. 001
Age range 20–99 17–83 18–100 18–98 NS
Male:female ratio 1:1.2 1:1.36 1:1 1:1.4 NS
comparable to that reported in Western population. Since
2008, selected patients admitted to medical wards, especially
those with acute respiratory failure, congestive heart failure,
sepsis underlying malignancy and restricted mobility might
be given DVT prophylaxis with low-molecular heparin at
physician’s discretion. We reported here the incidence of
proximal DVT among hospitalized Chinese medical patients
in 2008 and compare it with the proximal DVT incidence
from 2005–2007, a period when DVT prophylaxis was
generally not given.
2.Methods
2.1. Study Population. The Prince of Wales Hospital is a
general hospital in Hong Kong serving a population of over
one million. All Doppler ultrasound studies performed for
deep vein thrombosis for the period from 1 January 2005
to 31 December 2008 were reviewed. The medical records
of all cases of conﬁrmed proximal DVT were reviewed to
d e t e r m i n e( a )t h ep r e s e n c eo fr i s kf a c t o r s ,( b )t h en u m b e ro f
proximalDVT developedduringhospitalization in amedical
ward, (c) the number of patients readmitted with proximal
DVT within 14 days of discharge from a medical admission
of at least two days, (d) whether these patients had received
any DVT prophylaxisduring the current orpreviousmedical
admission.
The total number of admissions to the medical wards
during the study period was obtained from the hospital
statistics. We excluded short-stay admissions (less than
2 days) for procedures such as biopsy, bronchoscopy,
endoscopy,or blood transfusion from analysis. Only medical
admissions with a minimum stay of two days and proximal
DVT developing during hospitalization in medical wards
or readmission with a diagnosis of DVT within 14 days of
discharge from a recent admission to medical wards were
used to calculate the annual incidence of proximal DVT
among medical patients.
2.2. Doppler Ultrasound Study. A team of experienced
radiologists and qualiﬁed sonographers performed the
Doppler study using ultrasound scanner (Pulse Echo type
Model GELOG10-9). Absent or diminished Doppler ﬂow,
lack of respiratory variation, and failure to augment ﬂow
with maneuvers (calf compression) were used to establish
the diagnosis of proximal and distal DVT.
2.3. DVT Prophylaxis for Medical Patients. Patients admitted
with a diagnosis of acute respiratory failure, congestive heart
failure, sepsis, malignancy, obesity and restricted mobility
during hospitalization may be given DVT prophylaxis at the
discretionoftheattendingphysicians. Low-molecularweight
heparinisthemedicationmost commonlyprescribedforthis
purpose. In our hospital, prophylaxis was usually only given
for the hospital stay. It was rarely continued after discharge.
Doppler ultrasound will be performed whenever DVT was
suspected
2.4. Statistical Analysis. The impact of prophylaxis was
estimated by comparing the annual incidence of proximal
DVT amongmedical patientshospitalized from 2005to2007
with the 2008 annual incidence using chi-square test.
3.Results
From 1 January 2005 to 31 December 2008, 3938 Doppler
ultrasound studieswere performed forsuspected DVT.Prox-
imal DVT was diagnosed in 687 patients. Ofthese, 434(63%)
patients developed DVT during hospitalization. DVT
developed in these patients after at least 3 days of hospital
study (median 8 days, range 3–86 days). Two hundred and
ﬁfty-three (37%) subjects were admitted because of DVT
developing within 14 days (range 2–14 days, median 6 days)
of discharge from a previous medical admission. Median
in-hospital stay for the previous medical admissions was 13
days (range 2–166 days). Seventeen subjects had spiral CT
thorax documented pulmonary embolism. For the whole
group of 687 patients, the age ranged from 17 to 100, male
to female ratio was 1:1.24. The commonest risk factors were
malignancy (45%) followed by acute infections (24%), acute
respiratory failure (16%), congestive heart failure (14%),
and stroke (7%). The majority of the subjects (98%) did not
receive antithrombotic prophylaxis during the current or
previous admissions. There were no signiﬁcant diﬀerence in
age range sex ratio, and distribution of risk factors among
the patients who developed DVT during hospitalization
and those admitted with DVT. The calculated incidence of
proximal DVT among medical patients hospitalized for at
least two days were 1.8%, 2% and 1.7% for the year 2005,
2006and2007,respectively. Theincidencewas1.1%for2008
(P<. 001). The incidence of pulmonary embolism for 2005,
2006, 2007, and 2008 were 4, 4, 5, and 4 cases, respectively.
The incidence could be an underestimate because spiral CT
were usually performed on subjects with severe dyspnea or
hypoxia in the absence of heart failure or lung diseases. The
demographic proﬁles of patients who developed proximal
DVT from 2005–2008 were similar (Table 1).
4.Discussion
A majority of hospitalized patients have risk factors
for deep vein thrombosis and pulmonary embolism, andThrombosis 3
hospitalization for medical illness is associated with an eight-
fold-increased relative risk of VTE [13]. Fatal pulmonary
embolism accounts for 7 to 10% of all hospital-related
deaths,andmayaccountfordeathinupto1in200medically
illhospitalizedpatients[14].Randomizedtrialshavedemon-
strated the valueofprophylaxisforVTE in acutelyill medical
patients. The MEDENOX [6], PREVENT [7], and ARTEMIS
[8] studies showed statistically signiﬁcant reductions in VTE
versus. placebo by treatment with enoxaparin, dalteparin,
or fondaparinux, respectively. There was little data about
the incidence of DVT among Chinese patients admitted to
a medical ward. In the past, it was widely believed that
the incidence of DVT was much lower among the Chinese
population than Caucasians, and prophylaxis was generally
considered not necessary.
Our study showed an annual proximal DVT incidence
of 1.8–2% among Chinese patients admitted to the medical
wards for the period 2005–07. For patients with risk factors
such as malignancy, acute sepsis, acute respiratory failure
or congestive heart failure, there was a 2–4-fold-increase in
risk with incidence of 3.8–6.3% without prophylaxis [2].
Since 2008, there was increasing awareness that Chinese
patients were not immune to the development of DVY and
pulmonary embolism and the risk could be comparable to
Western population. More and more physicians were willing
prescribed antithrombotic therapy to hospitalized Chinese
patients with risk factors. Our data showed that there was a
signiﬁcant decreaseintheincidenceofproximalDVTamong
medical patients in 2008 when compared to the previous
years (1.1% versus 1.8–2%, P<. 001). The decrease could
be due to the increasing use of antithrombotic therapy as
there was no signiﬁcant diﬀerence in patient demographics
and distribution of risk factors between 2005–7 and 2008.
There are several limitations in our study. It was a
retrospective study which probably would underestimate the
true incidence of DVT. Many asymptomatic DVT would
be missed. The true incidence of DVT among hospitalized
Chinese patients without prophylaxis is uncertain. To obtain
such data, one needs to perform Doppler ultrasound study
prospectively on medical patients with various risk factors
and not on any antithrombotic prophylaxis. Secondly, DVT
prophylaxis was given at the discretion of the physicians
rather than according to protocols or standardized prac-
tice. Therefore, some high-risk subjects would not receive
any prophylaxis and vice versa. These would under esti-
mate the beneﬁts of DVT prophylaxis among Chinese
patients.
Thirdly, Doppler ultrasound study was performed only
in clinically suspected DVT cases. This may underestimate
the incidence of DVT in patients receiving prophylaxis.
However, thesame bias would applyto patientsnot receiving
prophylaxis.
In order to address the above limitations, we are now
conducting a prospective study to assess the eﬀectiveness
of DVT prophylaxis in acutely ill medical patients admitted
with respiratory failures, congestive heart failures or severe
sepsis. So far none of the 107 recruited subjects had
developedproximal DVT duringtheir hospital stayorwithin
3m o n t h so fd i s c h a r g e .
In conclusion, despite some limitations, our data did
suggest that proximal DVT was substantial in Chinese
medical patients and DVT prophylaxis might reduce such
risk.
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